Los Angeles, CA (PRWEB) May 17, 2015
On April 29, 2015, the Washington Post in article titled “The New Botox? FDA Approves an Injection to Fight Double Chins,” reported on the Food and Drug Administration’s approval of the injectable drug Kybella for improvement in the appearance of submental fat in adults. Kybella is the only non-surgical treatment with FDA approval for reducing double chins. Kybella is a synthetic version of deoxycholic acid, the body’s natural fat absorber. (see: goo.gl/xJwVIx)
“This may be a real breakthrough minimally invasive treatment,” says Dr. Simon Ourian, Medical Director of Epione Beverly Hills. “We can do a lot to tighten the skin in that area non-invasively that might work well in conjunction with the fat-destroying properties of Kybella.”
According to the Washington Post article, submental fat is often resistant to exercise and diet and there appears to be a substantial market for Kybella. Almost 70% of respondents to a 2014 American Dermatologic Surgery survey named excess fat under the chin as their number one aesthetic complaint.
“The clinical trials are over and the FDA has granted approval,” says Dr. Ourian. “In June, when the product becomes available, we will be able to gauge consumer reaction. At this point, we don’t even know what the product will cost.”
Dr. Ourian has been a pioneer in laser technology and non-invasive aesthetic procedures including UltraShape, VelaShape, Restylane, Juvéderm, Radiesse, Sculptra, and CoolSculpting. These treatments are used for the correction or reversal of a variety of conditions such as acne, acne scars, skin discoloration, wrinkles, unwanted fat, stretch marks, varicose veins, cellulite, and others. More information about plastic surgery can be found on Epione’s website.